| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/25/2007 | US7273876 Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use |
| 09/25/2007 | US7273875 Blocking tumor necrosis factor; antiinflammatory agents; respiratory system disorders; bronchodilator |
| 09/25/2007 | US7273874 Formed by reacting rapamycin or an analog with an optionally substituted olefin to fuse the C26NO2 ring with a vinylene group to form a fused cyclohexene ring, which may then be hydrogenated to a cyclohexane ring; neuroprotective agents |
| 09/25/2007 | US7273873 Camptothecins with a modified lactone ring |
| 09/25/2007 | US7273872 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages |
| 09/25/2007 | US7273871 tricyclic pyridines compounds, e.g., 1-(4-methoxy-2-methylphenyl)-7-methyl-5-(1-propyl-butyl)-1,2,2a, 3,4,5-hexahydro-1,5,8-triaza-acenaphtylene; CRF antagonists used for treatment of depression, anxiety, irritable bowel disease and inflammatory bowel disease |
| 09/25/2007 | US7273870 Stabilized difloxacin injectable solution |
| 09/25/2007 | US7273869 P-(aminomethyl)phenyl-substituted pyrazoloquinoxalines, imidazoquinoxalines, triazoloquinoxalines and benzoquinoxalines, e.g., N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methanamine; serine/threonine protein kinase inhibitors for treating cancer |
| 09/25/2007 | US7273868 excellent phosphodiesterase V (PDE V) inhibitory activity, and being useful as a remedy for the prophylaxis or treatment of penile erectile dysfunction with few side effects |
| 09/25/2007 | US7273867 Anticaogulants; cardiovascular disorders; Factor x inhibitors; antiinflammatory agents |
| 09/25/2007 | US7273866 2-aryl thiazole derivatives as KCNQ modulators |
| 09/25/2007 | US7273865 Alzheimer's disease; Parkinson's disease; antidepressants |
| 09/25/2007 | US7273864 inducing in vivo and in vitro differentiation and transdifferentiation of mammalian cells into cells of an osteoblast lineage |
| 09/25/2007 | US7273863 Benzophenones as inhibitors of reverse transcriptase |
| 09/25/2007 | US7273862 Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives |
| 09/25/2007 | US7273861 Non-nucleoside reverse transcriptase inhibitors |
| 09/25/2007 | US7273860 Administering compound such as (3S,2'R)-3-[1-(2'-carboxy-4'-phenylbutyl)cyclopentane-1-carbonylamino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid for therapy or inhibiting a nephropathy |
| 09/25/2007 | US7273859 Spiro-alkane, -tetrahydrofuranfuran, -tetrahydropyran, -pyrrolidine or -piperidine fused ring pyrimidinonecarboxamides, e.g., N-[(4-fluorophenyl)methyl]-7',8'-dihydro-3'-hydroxy-4'-oxo-spiro[cyclopentane-21,9'(6'H)-[4H]pyrido[1,2- alpha ]pyrimidine]-2'-carboxamide |
| 09/25/2007 | US7273858 Salts |
| 09/25/2007 | US7273857 Fused ring compounds substituted with a 8-azabicyclo[3.2.1]octane(cyclo)alkylene group, including benzothiazolones, e.g., 3-[3-(3-Propyl-8-aza-bicyclo[3.2.1]oct-8-yl)-propyl]-3H-benzothiazol-2-one; highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes |
| 09/25/2007 | US7273856 Antagonist of tachykinins like neurokinins and drugs |
| 09/25/2007 | US7273855 Single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3'UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been observed |
| 09/25/2007 | US7273854 Recombinant adenovirus, adeno-associated virus or herpes virus (especially a replication defective virus) containing a nucleic acid of a specific sequence encoding an antisense RNA that inhibits expression of p53. |
| 09/25/2007 | US7273853 6-11 bicyclic ketolide derivatives |
| 09/25/2007 | US7273852 Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| 09/25/2007 | US7273744 Heparanase-like polypeptides |
| 09/25/2007 | US7273717 Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B |
| 09/25/2007 | US7273716 Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase |
| 09/25/2007 | US7273715 Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A |
| 09/25/2007 | US7273625 Minari extract for preventing the induction and metastasis of cancer by carcinogens contained in cigarette smoke, fermented foods or alcoholic drinks |
| 09/25/2007 | US7273624 Stable dosage forms containing ubiquinones |
| 09/25/2007 | US7273623 Complex containing tannin; solid dosage form; sustained release |
| 09/25/2007 | US7273622 Soft gel capsule, beta-carotene; vitamin E; yellow beeswax;a mixture of mono-, di, tri-glycerides of 16 to 18 carbon chain length and polyglycerol oleate; rice bran oil |
| 09/25/2007 | US7273621 Compositions for promoting sleep |
| 09/25/2007 | US7273619 Minimized skin irritation |
| 09/25/2007 | US7273607 Comprises vitamins, minerals, amino acids, herbs, and essential oils; side effect reduction |
| 09/25/2007 | US7273606 Solubilized CoQ-10 and carnitine |
| 09/25/2007 | US7273604 Fine dry powder; rapidly spreads and melts over lung and air passageway surfaces |
| 09/25/2007 | US7273603 Aerosol solutions containing fluorohydrocarbons and drug |
| 09/25/2007 | US7273600 unit dose comprises a sufficient amount for in vivo diagnostic imaging of a 2'-deoxy-2'-[18F]- or a 3'-deoxy-3'-[18F]-labeled purine analog for being detected in vivo |
| 09/25/2007 | US7273453 Method for analyzing the biological age of a subject |
| 09/25/2007 | CA2547947C Azole derivatives as active superoxide radical inhibitors |
| 09/25/2007 | CA2511753C Phospholipid derivatives |
| 09/25/2007 | CA2484240C Packaged ocular irrigating solution bag |
| 09/25/2007 | CA2415551C Aniline derivatives |
| 09/25/2007 | CA2403026C Process for the preparation of 6-o-propargyl erythromycin derivatives |
| 09/25/2007 | CA2398848C Anti-infective agents useful against multidrug-resistant strains of bacteria |
| 09/25/2007 | CA2389766C New indenoindolone derivatives, the procedure for preparing them and the pharmaceutical compounds that contain them |
| 09/25/2007 | CA2388176C Therapeutic agent for eating disorders |
| 09/25/2007 | CA2386936C Antiviral compositions for tissue paper |
| 09/25/2007 | CA2376847C Complex of eletriptan and a cyclodextrin derivative |
| 09/25/2007 | CA2372025C Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
| 09/25/2007 | CA2370834C Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 09/25/2007 | CA2369302C Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| 09/25/2007 | CA2364446C Novel immunosuppressive agent |
| 09/25/2007 | CA2306257C 5-azaquinoxaline-based compounds and modulation of serine/threonine protein kinase function |
| 09/25/2007 | CA2305468C 8-azabicyclo [3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors |
| 09/25/2007 | CA2302585C Controlled release formulations |
| 09/25/2007 | CA2301183C Pharmacologic drug combination in vagal-induced asystole |
| 09/25/2007 | CA2294649C Bovine adenovirus type 3 genome |
| 09/25/2007 | CA2294607C Use of gaba analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| 09/25/2007 | CA2294278C Chalcones having antiproliferative activity |
| 09/25/2007 | CA2288650C A method for the treatment of mental illness in mammals and a composition therefor |
| 09/25/2007 | CA2269815C Thienopyrimidines having pde v-inhibiting action |
| 09/25/2007 | CA2256516C Peptides |
| 09/25/2007 | CA2245701C Mixtures derived from grains of eugenia jambolana lamarck, preparation and use of said mixtures and some of their constituents as medicaments |
| 09/25/2007 | CA2245094C Agglomerates |
| 09/25/2007 | CA2243317C Novel fused pyrrolecarboxamides; a new class of gaba brain receptor ligands |
| 09/25/2007 | CA2229077C Lipid metabolism improving agent |
| 09/25/2007 | CA2215692C Method of modulating microcirculation |
| 09/25/2007 | CA2204160C Treatment of urogenital cancer with boron neutron capture therapy |
| 09/25/2007 | CA2200967C Pharmaceutical compositions |
| 09/25/2007 | CA2177257C Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity |
| 09/25/2007 | CA2170242C Novel dietetic phospholipid compositions and use thereof as a dietary supplement |
| 09/25/2007 | CA2054686C Treatment of polycystic ovarian disease |
| 09/24/2007 | CA2571933A1 A descarbonylethoxyloratadine containing pharmaceutical composition |
| 09/24/2007 | CA2550702A1 Organic compounds |
| 09/24/2007 | CA2541045A1 A descarbonylethoxyloratadine containing pharmaceutical composition |
| 09/20/2007 | WO2007106892A2 Combined targeted therapy for the treatment of proliferative disease |
| 09/20/2007 | WO2007106886A2 Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy |
| 09/20/2007 | WO2007106884A2 Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| 09/20/2007 | WO2007106869A1 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use |
| 09/20/2007 | WO2007106854A2 Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
| 09/20/2007 | WO2007106852A2 Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods |
| 09/20/2007 | WO2007106792A2 Methods for treating sarcopenia with a growth hormone secretagogue |
| 09/20/2007 | WO2007106746A2 Formulations for ecallantide |
| 09/20/2007 | WO2007106721A2 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| 09/20/2007 | WO2007106706A1 Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders |
| 09/20/2007 | WO2007106705A1 Soluble epoxide hydrolase inhibitors and methods of using same |
| 09/20/2007 | WO2007106675A2 Composition and method of retarding viral activity and reducing viral replication |
| 09/20/2007 | WO2007106622A2 Fungicidal formulation and method of use |
| 09/20/2007 | WO2007106585A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 09/20/2007 | WO2007106561A2 Prevention and treatment of cancer and other diseases |
| 09/20/2007 | WO2007106554A2 Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds |
| 09/20/2007 | WO2007106550A2 Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| 09/20/2007 | WO2007106549A2 Method for treating brain cancer |
| 09/20/2007 | WO2007106525A1 Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
| 09/20/2007 | WO2007106508A2 Use of tetrahydropyridines in the treatment of central nervous system disorders |
| 09/20/2007 | WO2007106494A2 Methods and compositions for treatment of diastolic heart failure |
| 09/20/2007 | WO2007106488A2 Modulators of gluconeogenesis |